Allergic asthma is a chronic respiratory condition characterized by airway inflammation and constriction triggered by allergens, leading to recurrent wheezing and difficulty breathing. It often requires ongoing management with medications and allergen avoidance.

The rising prevalence of respiratory diseases is anticipated to drive the expansion of the allergic asthma therapeutics market. DelveInsight’s Asthma – Market Insights, Epidemiology and Market Forecast – 2032 report estimated that there were 55 million individuals with asthma in 2022. The gold standard treatment for allergic asthma involves a stepwise approach, starting with inhaled corticosteroids (ICS) as the cornerstone for reducing airway inflammation and then escalating therapy as needed with the addition of long-acting beta-agonists (LABAs) or biologics targeting specific inflammatory pathways, such as anti-IgE monoclonal antibodies or anti-IL-5 antibodies. Allergen avoidance, patient education, and lifestyle modifications are essential components of asthma management, aiming to achieve and maintain optimal asthma control while minimizing symptoms and exacerbations.

On Monday, September 11, 2023, at the European Respiratory Society (ERS) International Congress 2023 conference held in Milan, Italy, Foresee Pharmaceuticals presented a Late Breaking Abstract titled, “Effect of MMP-12 inhibitor, Adermastat (FP-025), on allergen-induced late response in asthmatic subjects,” showcasing the favorable primary results of its Aderamastat, Phase II proof-of-concept allergic asthma study.

Adermastat is a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, being evaluated for allergic asthmatic patients in a Phase II proof-of-concept study. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. The efficacy of multiple oral doses of Adermastat in HDM-allergic asthma was evaluated. FP-025 demonstrated a favorable safety profile and high tolerability in individuals with mild allergic asthma. Notably, it exhibited significant protection against allergen-induced LAR (FEV1 AUC-3-8), showcasing its potential as a valuable treatment option. Additionally, a carry-over effect upon FP-025 administration during Period 1 suggests the drug’s sustained efficacy over time. Ongoing analyses, including investigations into biomarkers and correlations, aim to provide deeper insights into the underlying mechanisms responsible for the observed efficacy.

DelveInsight’s Asthma – Market Insights, Epidemiology, and Market Forecast – 2032 estimated the asthma market to be USD 18,460 million in 2022. Adermastat, through its MMP-12 inhibition, holds promise in potentially mitigating airway remodeling, diminishing inflammation, safeguarding against lung injury and augmenting the responsiveness to current asthma treatments, potentially leading to better asthma management and patient well-being. Nevertheless, thorough clinical investigations are imperative to substantiate its safety and efficacy for broader application in the management of allergic asthma.